Navigation Links
New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
Date:9/18/2012

NEWTON, Mass., Sept. 18, 2012 /PRNewswire/ -- New England Cord Blood Bank, Inc. (NECBB) is pleased to announce that it now processes its cord blood using the Sepax 2 system from Biosafe.  Biosafe is the world leader in stem cell processing, serving stem cell banks, hospitals and research institutes alike with innovative cell processing solutions. 

Sepax 2 is a fully automated, mobile, closed capability system that provides the most efficient and consistent processing of umbilical cord blood. According to Brad Blaney, Laboratory Manager at NECBB, "From the day Sepax 2 was integrated into the lab, we saw a reduction in processing time and therefore an increase in our processing capacity.  The reliability, repeatability, and ease of use of the devices is great." The system involves processing of the umbilical cord blood via both its "plasma depletion" method and the "red cell reduction" method.  The Sepax system provides the NECBB client with exceptional post-thaw cell viability count.  This ensures that your family will have the greatest supply of high quality stem cells available should transplant become necessary.  Sepax processes every cord blood unit individually, respecting its biologic specificity and unique cell characteristics.

New England Cord Blood Bank, Inc. (NECBB) and its parent company, New England Cryogenic Center, Inc. have been pioneering forces in the cryogenic preservation of cells for over 30 years. At its International Headquarters, located just outside of Boston, Massachusetts, NECBB processes and stores lifesaving stem cells for thousands of families worldwide. Cord blood stem cells, obtained from the umbilical cord immediately following birth, are currently used to treat and cure more than 80 diseases. Successful transplants for cancer, anemia and other blood based diseases occur on a regular basis at approved transplant hospitals both domestically and internationally.

Most recently,
'/>"/>

SOURCE New England Cord Blood Bank
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
5. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
6. FindTheBest Helps Parents Find Cord Blood Banks
7. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
10. Study finds chronic abnormal brain blood flow in Gulf War veterans
11. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 9, 2011 HIGHLIGHTS:2010 Results (all percentages are ... reported sales were $582 million, a new quarterly high. Q4 sales ... basis, respectively.  Full year 2010 sales increased 6% and 5% on ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring costs of ...
... Spherix Incorporated (Nasdaq: SPEX ), an innovator ... atherosclerosis; and providers of technical and regulatory consulting services ... that its President, Dr. Robert Lodder, will be presenting ... to be held in New York next week. ...
... 8, 2011 United Therapeutics Corporation (Nasdaq: ... fourth quarter and annual 2010 financial results before market ... Therapeutics will host a half-hour teleconference on Tuesday, February ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Spherix to Present at the 13th Annual BIO CEO & Investor Conference 2Spherix to Present at the 13th Annual BIO CEO & Investor Conference 3
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... from the University of Liverpool's School of Biological Sciences have ... Gormley's 'Another Place' art installation on Crosby Beach have become ... barnacle - Elminius modestus. , Although the barnacles have been ... from half way across the world on the coasts of ...
... threat against the viabi lity of the Scandinavian wolf ... journal PLoS ONE now demonstrates that inbreeding is not ... show that it is the most genetically variable wolf ... important consequence of this action of natural selection is ...
... device currently used for intestinal research, the colonsope, causes ... has been developed, inspired by the way in which ... her PhD degree from TU Delft based on this ... difficult area to navigate through with a medical device. ...
Cached Biology News:Living laboratory found on shoreline statues 2Wolves are suffering less from inbreeding than expected 2Like a snail through the intestinal canal 2
Normal serum collected from healthy Kunming mice....
Request Info...
... This service involves the optimization ... includes titration of the primary ... secondary reagents (e.g. Alk. Phos., ... optimization of detection, evaluation by ...
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Biology Products: